LOGC Projected Dividend Yield
LogicBio Therapeutics Inc ( NASDAQ : LOGC )LogicBio Therapeutics is a clinical-stage genetic medicine company focused on genome editing and gene delivery platforms to address diseases from infancy through adulthood. Co.'s genome editing platform, GeneRide™, is an approach to gene insertion harnessing a cell's natural deoxyribonucleic acid repair process. Co.'s product candidate, LB-001, is a single-administration, genome editing therapy developed using its GeneRide technology for the treatment of methylmalonic acidemia in pediatric patients. Co.'s other product candidate, LB-401 is based on its GeneRide technology. LB-401 is a genome editing therapy being developed for the treatment of hereditary tyrosinemia type 1 in newborns. 20 YEAR PERFORMANCE RESULTS |
LOGC Dividend History Detail LOGC Dividend News LOGC Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |